ブルガリア - ブルガリア語 - Adama

adama - Емулсия, масло във вода (ЕВ) - 240 г/л тау-флувалинат - Инсектициди

欧州連合 - ブルガリア語 - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumab - melanoma; hodgkin disease; carcinoma, renal cell; carcinoma, non-small-cell lung; carcinoma, transitional cell; squamous cell carcinoma of head and neck; urologic neoplasms; mesothelioma; colorectal neoplasms - Антинеопластични средства - melanomaopdivo as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older. relative to nivolumab monotherapy, an increase in progression free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression. adjuvant treatment of melanomaopdivo as monotherapy is indicated for the adjuvant treatment of adults and adolescents 12 years of age and older with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. non-small cell lung cancer (nsclc)opdivo in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. opdivo as monotherapy is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer after prior chemotherapy in adults. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. malignant pleural mesothelioma (mpm)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. renal cell carcinoma (rcc)opdivo as monotherapy is indicated for the treatment of advanced renal cell carcinoma after prior therapy in adults. opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with intermediate/poor risk advanced renal cell carcinoma. opdivo in combination with cabozantinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma. classical hodgkin lymphoma (chl)opdivo as monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical hodgkin lymphoma after autologous stem cell transplant (asct) and treatment with brentuximab vedotin. squamous cell cancer of the head and neck (scchn)opdivo as monotherapy is indicated for the treatment of recurrent or metastatic squamous cell cancer of the head and neck in adults progressing on or after platinum based therapy. urothelial carcinomaopdivo as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum containing therapy. adjuvant treatment of urothelial carcinomaopdivo as monotherapy is indicated for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (miuc) with tumour cell pd-l1 expression ≥ 1%, who are at high risk of recurrence after undergoing radical resection of miuc. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)opdivo in combination with ipilimumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy. oesophageal squamous cell carcinoma (oscc)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo as monotherapy is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy. adjuvant treatment of oesophageal or gastro-oesophageal junction cancer (oc or gejc)opdivo as monotherapy is indicated for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy. gastric, gastro‑oesophageal junction (gej) or oesophageal adenocarcinomaopdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first‑line treatment of adult patients with her2‑negative advanced or metastatic gastric, gastro‑oesophageal junction or oesophageal adenocarcinoma whose tumours express pd-l1 with a combined positive score (cps) ≥ 5.

欧州連合 - ブルガリア語 - EMA (European Medicines Agency)

glaxo group ltd. - ампренавир - ХИВ инфекции - Антивирусни средства за системно приложение - agenerase, в комбинация с други антиретровирусными лекарства, които се предписват за лечение на протеазен инхибитор (ПИ) опитен hiv-1 инфектирани възрастни и деца над 4 години. Капсули agenerase, като правило, трябва да се прилага с ниска доза ritonavir, приемани като усилвател от фармакокинетиката ампренавира (виж раздели 4. 2 и 4. Изборът на ампренавир трябва да се основава на индивидуално изследване за вирусна резистентност и история на лечението на пациентите (вж. Точка 5. В полза на agenerase силен ritonavir не е доказана при пациенти ПИ главини (виж раздел 5.

欧州連合 - ブルガリア語 - EMA (European Medicines Agency)

dompé biotec s.p.a. - дарбепоетин алфа - kidney failure, chronic; anemia; cancer - Антианемични препарати - Лечение на симптоматична анемия, свързана с хронична бъбречна недостатъчност (crf) при възрастни и педиатрични пациенти. Лечение на симптоматична анемия при възрастни онкологични пациенти, с миелоидными злокачествени заболявания, подложени на химиотерапия.

欧州連合 - ブルガリア語 - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - Телмисартан - Хипертония - Сърдечносъдова система - Лечение эссенциальной хипертония при възрастни:добавяне на therapyonduarp, се посочва в възрастни, чието кръвно налягане не се контролира адекватно амлодипином. Подмяна на therapyadult на пациентите за получаване на телмисартан и Амлодипин от индивидуалните таблетки могат да се появят хапчета onduarp съдържащи еднакви дози компонент .

欧州連合 - ブルガリア語 - EMA (European Medicines Agency)

biomarin international limited - Сапроптерин дихидрохлорид - phenylketonurias - Други стомашно-чревния тракт и обмяната на веществата средства, - kuvan е показан за лечение на хиперфенилаланинемия (ХПК) при възрастни и педиатрични пациенти на всички възрасти с фенилкетонурия (ПКК), за които е доказано, че отговарят на такова лечение. Кувинский също така е показан за лечение на hyperphenylalaninaemia (ГПА) при възрастни и педиатрични пациенти от всички възрасти с tetrahydrobiopterin (СҺ4) недостатък, който са показали, че ще реагира на такова лечение.

欧州連合 - ブルガリア語 - EMA (European Medicines Agency)

instituto grifols s.a. - Имуноглобулин нормален човек - mucocutaneous lymph node syndrome; guillain-barre syndrome; bone marrow transplantation; purpura, thrombocytopenic, idiopathic; immunologic deficiency syndromes - Имунни серуми и имуноглобулини - replacement therapy in adults, children and adolescents (0-18 years) in: , primary immunodeficiency syndromes with impaired antibody production;, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed;, hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation;, hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (hsct);, congenital aids with recurrent bacterial infections. , immunomodulation in adults, children and adolescents (0-18 years) in: , primary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, guillain barré syndrome;, kawasaki disease.

欧州連合 - ブルガリア語 - EMA (European Medicines Agency)

intervet international bv - indoxacarb, permethrin - перметрин, комбинации, ectoparasiticides за външно приложение, включително. инсектициди - Кучета - Лечение на инфестации с бълхи (ctenocephalides felis); продуктът има устойчива инсектицидна ефикасност до 4 седмици срещу ctenocephalides felis. Продуктът има устойчива акарицидна ефикасност до 5 седмици срещу ixodes ricinus и до 3 седмици срещу rhipicephalus sanguineus. Едно лечение осигурява репелентна (анти-хранеща) активност срещу пясъчни мухи (phlebotomus perniciosus) за период до 3 седмици.

欧州連合 - ブルガリア語 - EMA (European Medicines Agency)

pharmaxis europe limited - манитол - Кистозна фиброза - Кашлица и студени препарати - Бронхитол е показан за лечение на кистозна фиброза (cf) при възрастни на и над 18 години като допълнителна терапия за най-добър стандарт на грижа.

欧州連合 - ブルガリア語 - EMA (European Medicines Agency)

baxalta innovations gmbh - Имуноглобулин нормален човек - Синдроми на имунологична недостатъчност - Имунни серуми и имуноглобулини - Заместителна терапия при възрастни, деца и юноши (0-18 години) в:синдроми на първичен имунен с нарушение на антителообразования. hypogammaglobulinaemia и рецидивиращи бактериални инфекции при пациенти с хроничен лимфолейкозом (ХЛЛ), в които превантивни антибиотици са неефективни или са противопоказани. hypogammaglobulinaemia и рецидивиращи бактериални инфекции при множествена миеломе (мм) пациенти. hypogammaglobulinaemia при пациенти преди и след аллогенной трансплантация на хемопоетични стволови клетки (ТГСК).